Intellia Therapeutics, Inc. (NTLA) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.77B USD. 52-week range 7.95 to 28.25 USD. Data as of 2026-10-09.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or ...